Randomized, delayed start, double blind, parallel group, placebo controlled, multicenter study of piromelatine 20 mg in participants with mild dementia due to Alzheimer's disease
Stopped early
Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are 2:107,510,000-107,540,000 polymorphism non-carriers with the primary objective to compare the effect of piromelatine to that of pla…
Phase 2/3 • Sponsor: Neurim Pharmaceuticals Ltd.
Last updated Sep 09, 2026 16:00 UTC